Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
Phase of Trial: Phase II
Latest Information Update: 17 May 2019
At a glance
- Drugs Cabozantinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.